You are here


The real lesson from Eli Lilly's Alzheimer's drug trial failure

Digging through unsuccessful drug experiments to find justification for moving forward with medicines is a recipe for failing again.

New York

THE most anticipated pharma news of 2016 lived down to expectations.   Following in the footsteps of nearly every other company that has sought to treat Alzheimer's disease, Eli Lilly announced last Wednesday that its Alzheimer's drug solanuzemab (sola) failed a huge Phase 3...

Market voices on: